- Home >
- Clinicals Trials >
- IMMUNO-BIL (D48-1 PRODIGE 57)
IMMUNO-BIL (D48-1 PRODIGE 57)
Durvalumab Plus Tremelimumab Combination Immunotherapy With or Without Weekly Paclitaxel in Patients With Advanced Biliary Tract Carcinoma (BTC) After Failure of Platinum-based Chemotherapy: a Randomized Non-comparative Two-arm Phase II Study
- Open at Saint-Cloud since : 09/11/2018
- Target : Adult
- Phase : Phase II
Trial description
IMMUNO-BIL is a non-comparative randomized 1:1 phase II study. This study will assess the efficacy and safety of the combination of durvalumab plus tremelimumab with or without weekly paclitaxel in patients with advanced BTC after failure of platinum-based chemotherapy.
Url of the trial